Patient-based disease models carry a huge potential for phenotypic drug discovery and the generation of more efficient drugs. Aligning Europe’s best experts from academia and industry, we conduct most valuable drug discovery programs in a from-bed-to-bench-and-back-to-bed cycle.
With a strong focus on monogenic diseases we design most authentic disease models with isogenic healthy controls. Based on patient-derived induced pluripotent stem cells, differentiated into disease relevant cell types, our models benefit from a whole set of proprietary technologies for cell differentiation and large-scale production.
After phenotypic and functional validation, these models are transformed into fully automated assays. Our capacity to develop tailored AI-based algorithms for image analysis allows their application for large phenotypic screening campaigns.
In a second step, we combine our assays with large compound libraries of up to 200 000 compounds for the identification and development of valuable first-in-class compounds.